– USA, NY – Athenex, Inc announced today that Mr. Antony Leung has accepted the invitation to join the Athenex Board of Directors.
Antony Leung, Hon.LLD, GBS, JP, former Financial Secretary of Hong Kong Special Administrative Region, is currently Group CEO of Nan Fung Group, a leading regional conglomerate focusing on property & investment businesses. He is also Independent Non-Executive Director of China Merchants Bank, Chairman of charity organizations Heifer International Hong Kong and Food Angel, and Chairman of Harvard Business School Association of Hong Kong. Mr. Leung has extensive experience in financial services, including Chairman of Greater China of Blackstone, Chairman of Asia of JP Morgan Chase, Asia Head of Citi Private Bank, Regional Head of Citi Investment Bank, Treasury and Greater China. In addition, he was independent director of Industrial and Commercial Bank of China, China Mobile (Hong Kong) Limited, American International Assurance (Hong Kong) Limited, and international advisory board member of China Development Bank. His past public service includes Non-Official Member of the Executive Council, member of the Exchange Fund Advisory Committee, Hong Kong Airport Authority, Chairman of the Education Commission and University Grants Committee in Hong Kong. Mr. Leung graduated from the University of Hong Kong in 1973, and attended Harvard Business School’s Program for Management Development and Advanced Management Program. For his public service in Hong Kong, he was awarded the Gold Bauhinia Star by the Hong Kong Government and an Officer of the Most Excellent Order of the British Empire. He was conferred an honorary Doctor of Law by the Hong Kong University of Science and Technology.
The Right Honorable Kim Campbell, Chairperson of the Nominating and Corporate Governance Committee and 19th Prime Minister of Canada, stated, “It is an honor to have Antony join our Board. Antony’s executive experience in internationally based banking and investment companies focused in China, including his current role as Group CEO of the Nan Fung Group and former Chairman of Blackstone Greater China, will be extremely helpful to our Company during this stage of rapid growth. His experience as the former Financial Secretary of Hong Kong Special Administrative Region will certainly assist us to navigate through our business strategy of bridging the United States and Greater China in the sector of biotechnology/specialty pharmaceuticals, with the ultimate aim to improve the lives of cancer patients everywhere.”
Laureate Dr. Manson Fok, Chairman of Pedder Clinic and Dean of Health Sciences, Macau University of Science and Technology and a member of the Athenex Nominating and Corporate Governance, said, “It is great to have Antony joining our Board. His business skill set will complement our Board and we share the same commitment to humanity and Athenex, to develop better medicines for cancer patients.”
Mr. Leung commented, “Athenex is an exciting biotechnology/specialty pharmaceutical company. I came to know Athenex through an investment of the Nan Fung Group. The Athenex business model is a hybrid between scientific and business innovations and it has a very strong management team. I have personally witnessed their excellent execution and their pro-growth strategy between US and Greater China, including Hong Kong. I believe that Athenex will play a key role going forward as an innovator in the biotechnology/specialty pharmaceutical sector between US and Greater China and I and the Nan Fung Group will be more than happy to assist them in their mission, which we believe we translate into not just a business, but also for the better healthcare for patients everywhere.”
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
